NIH RePORTER
Cure8 research brief
Why This Matters
People with HαT report GI symptoms often labeled IBS; this study aims to test whether intestinal barrier dysfunction and specific food proteins trigger mucosal and mast-cell responses that could explain symptoms. If confirmed, findings could point toward objective tests and diet-based strategies for symptomatic HαT.
Who Should Pay Attention
Researchers studying mast-cell disorders, clinicians treating patients with HαT, gastroenterologists interested in food-triggered intestinal barrier dysfunction, and adult patients with HαT or unexplained IBS-like symptoms.
Study Snapshot
Story typeClinical Reference
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is a funded NIH Reporter project record proposing to study intestinal involvement in symptomatic hereditary alpha-tryptasemia (HαT).
The study will use confocal laser endomicroscopy (CLE) to assess baseline intestinal barrier dysfunction and to perform intra-duodenal food challenges (wheat, soy, milk proteins, tomatoes and others) with immediate CLE assessment.
Investigators will correlate CLE findings with noninvasive intestinal permeability markers (urinary lactulose-mannitol, serum/fecal zonulin, LPS-binding protein, sCD14) and mast cell activation measures (urinary mediators, fecal/intraduodenal eosinophilic cationic protein, intraduodenal mature tryptase).
The project aims to define diet-triggered mucosal responses and characterize HαT as an enteropathy with epithelial barrier dysfunction. The description comes from the NIH project abstract (project-record). It outlines aims, methods, and candidate biomarkers but does not report results.
It is a research protocol/funded project rather than a completed clinical trial or published paper. Do not interpret planned assessments as findings.
Keep In Mind
This is a funded study protocol (project-record) describing planned research and methods rather than published results. Any implications for diagnosis or treatment will depend on study findings and further validation. Some assays and CLE are specialized and may not be widely available.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsAmelie Therrien
InstitutionBETH ISRAEL DEACONESS MEDICAL CENTER
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedJul 15, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R21AI196617 - $306,533
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
GI Permeability Change in Response to Aquamin®
Changes in gut permeability are thought to relate to intestinal barrier function and symptoms in UC and IBS-D. If Aquamin alters permeability, it could suggest a mechanism for symptom or disease-modifying effects and...
A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disorders
A validated human peristaltic intestinal organoid model could make preclinical testing more predictive for drugs affecting gut motility and reduce reliance on animal models.
What Causes Crohn's Disease Symptoms When Inflammation Isn't Present? - HealthCentral
This study offers a noninflammatory explanation for why many people with Crohn’s continue to have symptoms despite controlled inflammation: sulfur-producing gut microbes and their hydrogen sulfide byproduct. That could...